Dr. Rudin on Rova-T in Patients With Small Cell Lung Cancer

1 Views
administrator
administrator
07/14/23

Charles M. Rudin, MD, medical oncologist, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of single-agent rovalpituzumab tesirine (Rova-T) in patients with recurrent or refractory small cell lung cancer (SCLC).

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next